PMID- 28123609
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1837-9664 (Print)
IS  - 1837-9664 (Electronic)
IS  - 1837-9664 (Linking)
VI  - 8
IP  - 1
DP  - 2017
TI  - Low Incidence along with Low mRNA Levels of EGFR(vIII) in Prostate and Colorectal 
      Cancers Compared to Glioblastoma.
PG  - 146-151
LID - 10.7150/jca.16108 [doi]
AB  - Background: The presence as well as the potential role of EGFR(vIII) in tumors 
      other than glioblastoma still remains a controversial subject with many 
      contradictory data published. Previous analyses, however, did not consider the 
      level of EGFR(vIII) mRNA expression in different tumor types. Methods: 
      Appropriately designed protocol for Real-time quantitative reverse-transcription 
      PCR (Real-time qRT-PCR) was applied to analyze EGFR(vIII) and EGFR(WT) mRNA 
      expression in 155 tumor specimens. Additionally, Western Blot (WB) analysis was 
      performed for selected samples. Stable cell lines showing EGFR(vIII) expression 
      (CAS-1 and DK-MG) were analyzed by means of WB, immunocytochemistry (ICC) and 
      fluorescence in situ hybridization (FISH). Results: Our analyses revealed 
      EGFR(vIII) expression in 27.59% of glioblastomas (8/29), 8.11% of colorectal 
      cancers (3/37), 6.52% of prostate cancers (3/46) and none of breast cancers 
      (0/43). Despite the average relative expression of EGFR(vIII) varying greatly 
      among tumors of different tissues (approximately 800-fold) or even within the 
      same tissue group (up to 8000-fold for GB), even the marginal expression of 
      EGFR(vIII) mRNA can be detrimental to cancer progression, as determined by the 
      analysis of stable cell lines endogenously expressing the oncogene. Conclusion: 
      EGFR(vIII) plays an unquestionable role in glioblastomas with high expression of 
      this oncogene. Our data suggests that EGFR(vIII) importance should not be 
      underestimated even in tumors with relatively low expression of this oncogene.
FAU - Peciak, Joanna
AU  - Peciak J
AD  - Department of Research and Development, Celther Polska, Ltd., Milionowa 23, 
      93-193 Lodz, Poland;; Department of Tumor Biology, Medical University of Lodz, 
      Zeligowskiego 7/9, 90-752 Lodz, Poland.
FAU - Stec, Wojciech J
AU  - Stec WJ
AD  - Department of Research and Development, Celther Polska, Ltd., Milionowa 23, 
      93-193 Lodz, Poland.
FAU - Treda, Cezary
AU  - Treda C
AD  - Department of Research and Development, Celther Polska, Ltd., Milionowa 23, 
      93-193 Lodz, Poland;; Department of Tumor Biology, Medical University of Lodz, 
      Zeligowskiego 7/9, 90-752 Lodz, Poland.
FAU - Ksiazkiewicz, Magdalena
AU  - Ksiazkiewicz M
AD  - Department of Research and Development, Celther Polska, Ltd., Milionowa 23, 
      93-193 Lodz, Poland.
FAU - Janik, Karolina
AU  - Janik K
AD  - Department of Research and Development, Celther Polska, Ltd., Milionowa 23, 
      93-193 Lodz, Poland;; Department of Tumor Biology, Medical University of Lodz, 
      Zeligowskiego 7/9, 90-752 Lodz, Poland.
FAU - Popeda, Marta
AU  - Popeda M
AD  - Department of Research and Development, Celther Polska, Ltd., Milionowa 23, 
      93-193 Lodz, Poland.
FAU - Smolarz, Maciej
AU  - Smolarz M
AD  - Department of Research and Development, Celther Polska, Ltd., Milionowa 23, 
      93-193 Lodz, Poland.
FAU - Rosiak, Kamila
AU  - Rosiak K
AD  - Department of Research and Development, Celther Polska, Ltd., Milionowa 23, 
      93-193 Lodz, Poland;; Department of Tumor Biology, Medical University of Lodz, 
      Zeligowskiego 7/9, 90-752 Lodz, Poland.
FAU - Hulas-Bigoszewska, Krystyna
AU  - Hulas-Bigoszewska K
AD  - Department of Research and Development, Celther Polska, Ltd., Milionowa 23, 
      93-193 Lodz, Poland.
FAU - Och, Waldemar
AU  - Och W
AD  - Clinical Department of Neurosurgery, The Voivodal Specialistic Hospital in 
      Olsztyn, Zolnierska 18, 10-561 Olsztyn, Poland.
FAU - Rieske, Piotr
AU  - Rieske P
AD  - Department of Research and Development, Celther Polska, Ltd., Milionowa 23, 
      93-193 Lodz, Poland;; Department of Tumor Biology, Medical University of Lodz, 
      Zeligowskiego 7/9, 90-752 Lodz, Poland.
FAU - Stoczynska-Fidelus, Ewelina
AU  - Stoczynska-Fidelus E
AD  - Department of Research and Development, Celther Polska, Ltd., Milionowa 23, 
      93-193 Lodz, Poland;; Department of Tumor Biology, Medical University of Lodz, 
      Zeligowskiego 7/9, 90-752 Lodz, Poland.
LA  - eng
PT  - Journal Article
DEP - 20170101
PL  - Australia
TA  - J Cancer
JT  - Journal of Cancer
JID - 101535920
PMC - PMC5264051
OTO - NOTNLM
OT  - EGFRvIII
OT  - Real-time quantitative reverse-transcription PCR.
OT  - breast cancer
OT  - colorectal cancer
OT  - glioblastoma
OT  - prostate cancer
COIS- The authors have declared that no competing interest exists.
EDAT- 2017/01/27 06:00
MHDA- 2017/01/27 06:01
PMCR- 2017/01/01
CRDT- 2017/01/27 06:00
PHST- 2016/05/09 00:00 [received]
PHST- 2016/10/15 00:00 [accepted]
PHST- 2017/01/27 06:00 [entrez]
PHST- 2017/01/27 06:00 [pubmed]
PHST- 2017/01/27 06:01 [medline]
PHST- 2017/01/01 00:00 [pmc-release]
AID - jcav08p0146 [pii]
AID - 10.7150/jca.16108 [doi]
PST - epublish
SO  - J Cancer. 2017 Jan 1;8(1):146-151. doi: 10.7150/jca.16108. eCollection 2017.